{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T18:14:22Z","timestamp":1776363262915,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01420-8","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:56:48Z","timestamp":1764255408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies"],"prefix":"10.1038","volume":"15","author":[{"given":"Lockwood","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6492-4808","authenticated-orcid":false,"given":"Amy","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1420_CR1","unstructured":"U. S. Food and Drug Administration. Clinical Review - ABECMA. Posted online April 4, 2024. Accessed July 18, 2025. https:\/\/www.fda.gov\/media\/177864\/download?attachment"},{"key":"1420_CR2","unstructured":"U.S. Food and Drug Administration. Clinical Review and Evaluation - CARVYKTI. Posted online April 5, 2024. Accessed July 18, 2025. https:\/\/www.fda.gov\/media\/178689\/download?attachment"},{"key":"1420_CR3","unstructured":"U. S. Food and Drug Administration. Highlights of prescribing information: SARCLISA. U. S. Food and Drug Administration. Posted online July 9, 2020. Accessed July 18, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761113s012lbl.pdf"},{"key":"1420_CR4","unstructured":"U. S. Food and Drug Administration. Highlights of prescribing information: DARZALEX FASPRO. U. S. Food and Drug Administration. Posted online July 10, 2020. Accessed July 18, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761145s000lbl.pdf"},{"key":"1420_CR5","unstructured":"U. S. Food and Drug Administration. U.S. Congress. 21st Century Cures Act, Public Law 114\u2013255 114th Congress An Act. Posted online July 7, 2016. Accessed July 18, 2025. https:\/\/www.congress.gov\/114\/plaws\/publ255\/PLAW-114publ255.pdf"},{"key":"1420_CR6","unstructured":"European Medicines Agency. Use of real\u2011world evidence in regulatory decision\u2011making\u2013 EMA publishes review of its studies. June 23, 2023. Accessed July 18, 2025. https:\/\/www.ema.europa.eu\/en\/news\/use-real-world-evidence-regulatory-decision-making-ema-publishes-review-its-studies"},{"key":"1420_CR7","unstructured":"U. S. Food and Drug Administration. Real\u2011World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision\u2011Making for Drug and Biological Products. Guidance for Industry. Posted online July 18, 2024. Accessed July 18, 2025. https:\/\/www.fda.gov\/media\/152503\/download"},{"key":"1420_CR8","unstructured":"U. S. Food and Drug Administration. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drugs and biological products. July 14, 2023. Accessed July 18, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug"},{"key":"1420_CR9","unstructured":"Albagoush SA, Shumway C, Azevedo AM Multiple Myeloma. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. Treasure Island (FL): StatPearls Publishing; 2023. Accessed July 18, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534764\/"},{"key":"1420_CR10","doi-asserted-by":"publisher","unstructured":"Arondekar B, Duh MS, Bhak RH, DerSarkissian M, Huynh L, Wang K, et al. Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. Clin Cancer Res. 2021;28:clincanres.2639.2021. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-2639","DOI":"10.1158\/1078-0432.ccr-21-2639"},{"key":"1420_CR11","unstructured":"European Medicines Agency. Assessment report: Carvykti. March 24, 2022. Accessed September 16, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/carvykti-epar-public-assessment-report_en.pdf"},{"key":"1420_CR12","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1182\/blood-2021-144387","volume":"138","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Cornell RF, Callander NS, Chhabra S, Liedtke M, Kansagra A, et al. Efficacy of treatments for patients with triple-class refractory (TCR) multiple myeloma (MM): benchmark for new agents utilizing real-world data (RWD). Blood. 2021;138:3786. https:\/\/doi.org\/10.1182\/blood-2021-144387.","journal-title":"Blood"},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/nejmoa2024850.","journal-title":"N Engl J Med"},{"key":"1420_CR14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1420_CR15","unstructured":"European Medicines Agency. Elrexfio (Elranatamab): EPAR \u2013 Public Assessment Report. EMA\/544323\/2023.; 2023. Accessed July 18, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/elrexfio-epar-public-assessment-report_en.pdf"},{"key":"1420_CR16","doi-asserted-by":"publisher","first-page":"e1610068","DOI":"10.1097\/01.hs9.0000967700.16100.68","volume":"7","author":"HC Lee","year":"2023","unstructured":"Lee HC, Bumma N, Richter J, Dhodapkar M, Hoffman JE, Suvannasankha A, et al. S197: linker-Mm1 study: linvoseltamab (Regn5458) in patients with relapsed\/refractory multiple myeloma. HemaSphere. 2023;7:e1610068. https:\/\/doi.org\/10.1097\/01.hs9.0000967700.16100.68.","journal-title":"HemaSphere"},{"key":"1420_CR17","unstructured":"European Medicines Agency. Data Quality Framework for EU Medicines Regulation: Application to Real-World Data; 2024. Accessed July 18, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/other\/draft-data-quality-framework-eu-medicines-regulation-application-real-world-data_en.pdf"},{"key":"1420_CR18","unstructured":"Celgene. Abecma BLA Clinical Review Memorandum. March 26, 2025. Accessed September 16, 2025. https:\/\/fda.report\/media\/147740\/Clinical+Review+Memo%2C+March+26%2C+2021+-+ABECMA.pdf"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01420-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:56:53Z","timestamp":1764255413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01420-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time of the study, Dr. Taylor, Dr. Chen, and Mrs. Pierre reported employment at Flatiron Health, Inc.\u2014an independent member of the Roche Group\u2014and stock ownership in Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}